AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00716664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A treatment series of gentle joint and muscle movements
Description: Undertaken by a physiotherapist, weekly, for six weeks
Study NCT00716664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group measurements
Description: The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
Study NCT02571543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT01363947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02427620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT02427620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03612414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aqualief
Description: Three tablets/day
Study NCT03612414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three tablets/day
Study NCT04421664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
Study NCT01433653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Complicated Grief
Description: Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
Study NCT04421664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
Study NCT02202265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: 30ml a day of olive oil
Study NCT02202265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuts
Description: 30g a day of nuts
Study NCT02202265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Diet based on standard guidelines
Study NCT01723839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
Description: 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
Study NCT04241432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrating platform
Description: Use of two different types of vibrating platform
Study NCT02466997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
Study NCT02466997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00600704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Restriction Policy
Description: Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
Study NCT00600704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free fluid infusion
Description: Free fluid infusion unless Hb\< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
Study NCT01509404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valcyte per package insert guidelines for 200 days post transplant
Study NCT01509404 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CMV hyperimmune globulin
Description: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Study NCT01509404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Study NCT04377256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation: Tooth extration and immediat bone grafting in the socket
Description: Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
Study NCT02735642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Randomization 1 - Referral
Description: Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
Study NCT02735642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Randomization 1 - Referral and SMS
Description: Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
Study NCT00355667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: Patients with chronic heart failure receive furosemide and other standard treatment/
Study NCT00355667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azosemide
Description: Patients with chronic heart failure receive azosemide and other standard treatment.
Study NCT01403987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residency Program Teaching
Description: The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
Study NCT01403987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residency Program Teaching
Description: The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
Study NCT01403987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lecture
Description: During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
Study NCT01403987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pocket Card Reference
Description: A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
Study NCT02735642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Randomization 2 - SMS
Description: Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
Study NCT02735642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Randomization 2 - Incentive
Description: Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
Study NCT02735642 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High Risk Negative Cohort (N=185)
Description: A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
Study NCT02735642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: All participants. Approximately (N=1200)
Description: HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire.
Study NCT02075684 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Biopsy
Study NCT04680208 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical procedure under anesthesia
Description: Different varieties of surgical procedures done under anesthesia
Study NCT03871504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal isometric exercise
Description: The exercise is a submaximal isometric contraction
Study NCT02039206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep TMS
Description: 1Hz Stimulation
Study NCT01403987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pager
Description: The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a tap, the pager number will correlate with the letters, TAPS, or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure.
Study NCT03522428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin b12
Description: Vitamin B12 has been added to the experimental group of pregnant women, at a dose of 5 μg / 100 days
Study NCT01345903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo robotic-assisted surgery
Study NCT01918020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go Wild with Fruits and Veggies!
Description: Fruits and Vegetables
Study NCT01918020 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Go Wild with Fruits and Veggies! delayed
Description: Go Wild with Fruits and Veggies! delayed
Study NCT03160573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClōSYS® Unflavored Rinse
Study NCT03160573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClōSYS® Flavored Rinse
Study NCT03160573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Flavored Oral Rinse
Description: Flavor-matched placebo rinse
Study NCT03160573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Unflavored Oral Rinse
Description: Unflavored-matched placebo rinse
Study NCT00488293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Store and forward teledermatology
Description: Standard electronic consult, standardized history, and image set
Study NCT03906955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Efficacy for Lifestyle PA
Description: The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.
Study NCT03906955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy for Work-life Balance
Description: The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
Study NCT01276535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia MLS + Erchonia THL
Description: The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.~The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.~Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.~The intent is to evaluate the effectiveness of Erchonia MLS \& Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL
Study NCT04021368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120(SEL120)
Description: RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
Study NCT02324907 — intervention group
Intervention type: DEVICE
Intervention: Procedure/Surgery
Description: Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
Study NCT02416479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE
Description: SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
Study NCT02416479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-education attention control
Description: The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
Study NCT03752372 — intervention group
Intervention type: PROCEDURE
Intervention: hematopoietic stem cell transplantation
Description: 1. Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~2. All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~3. Umbilical cord blood transplantation
Study NCT04127110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: (30 mg/m2 D1 + D8 as infusion) cycle Q3W
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: (30 mg/m2 D1 + D8 as infusion) cycle Q3W
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: (1000 mg/m2 D1 + D8 as infusion) cycle Q3W
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: (1000 mg/m2 D1 + D8 as infusion) cycle Q3W
Study NCT05745532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: β-globin restored autologous hematopoietic stem cells
Description: β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: (100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: (100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: (AUC = 5 mg•min/mL on Day 1) cycle Q3W
Study NCT03345810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: (AUC = 5 mg•min/mL on Day 1) cycle Q3W
Study NCT00382863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartNet Ventricular Support System
Description: The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
Study NCT00382863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical/Device Therapy
Description: Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
Study NCT02016885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate, 1.0%
Description: glycopyrrolate Topical Wipes, 1.0%
Study NCT02016885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate, 2.0%
Description: glycopyrrolate Topical Wipes, 2.0%
Study NCT02016885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate, 3.0%
Description: glycopyrrolate Topical Wipes, 3.0%
Study NCT02016885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate, 4.0%
Description: glycopyrrolate Topical Wipes, 4.0%
Study NCT02016885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Topical Wipes
Study NCT04469946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oticon OpenSound Navigator speech enhancement algorithm
Description: OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
Study NCT02474511 — intervention group
Intervention type: OTHER
Intervention: general anesthesia and local anesthesia
Description: the patient received generalanesthesia and local anesthesia randomly
Study NCT03950401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl
Description: subcuticular Monocryl wound closure